Autism: An emerging 'neuroimmune disorder' in search of therapy

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 13, 2009, Pages 2127-2143

  Theoharides, Theoharis C ^a   Kempuraj, Duraisamy ^a   Redwood, Lyn ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Coalition for Safe Minds and the National Autism Association ^*  (United States)

Author keywords

Autism; Blood brain barrier; Cytokines; Flavonoids; Inflammation; Intestine; Mast cells; Mastocytosis; Oxidative stress; Psychotropic agents; Treatment

Indexed keywords

ANTIOXIDANT; CHONDROITIN SULFATE; CROMOGLYCATE DISODIUM; CYPROHEPTADINE; FLAVONOID; HALOPERIDOL; KETOTIFEN; LUTEOLIN; METHYLPHENIDATE; NALTREXONE; NEUROPROTEK; OLANZAPINE; PROTEOGLYCAN; PSYCHOTROPIC AGENT; QUERCETIN; RISPERIDONE; RUPATADINE; UNCLASSIFIED DRUG;

AGGRESSION; ALLERGY; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; CELL ACTIVATION; CLINICAL TRIAL; ENCEPHALITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERACTIVITY; IMMUNE DYSREGULATION; MAST CELL; MASTOCYTOSIS; NEUROIMMUNOLOGY; NONHUMAN; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SEDATION; SIDE EFFECT; STEREOTYPY; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT INDICATION; WEIGHT GAIN;

AUTISTIC DISORDER; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE SYSTEM; NERVOUS SYSTEM; NEUROIMMUNOMODULATION; OXIDATIVE STRESS;

EID: 68949159751     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903107789     Document Type: Review

References (215)

1. Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006;118(1):e139-50 (Pubitemid 46071129)
2. Gerberding J. Prevalence of autism spectrum disorder-Autism and developmental disabilities monitoring network, six sites, United States, 2000 and 2002. MMWR Morb Mortal Wkly Rep 2007;56(1S):1-40
3. Newschaffer CJ, Croen LA, Daniels J, et The epidemiology of autism spectrum disorders. Annu Rev Public Health 2007;28:235-258
4. Yeargin-Allsopp M, Rice C, Karapurkar T, et al. Prevalence of autism in a US metropolitan area. JAMA 2003;289(1):49-55
5. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006;160(8):825-830
6. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007;120(5):1183-1215 (Pubitemid 350085561)
7. Center for disease control: prevalence of autism spectrum disorders -autism and developmental disabilities monitoring network, six sites, 2000. Morb Mortal Wkly Rep 2007;15:1-11
8. Kuehn BM. CDC: autism spectrum disorders common. JAMA 2007;297(9):940 (Pubitemid 46376769)
9. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009;65(6):591-598 Most recent review of all published studies on the prevalence of autism.
10. Hertz-Picciotto I, Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 2009;20(1):84-90
11. Stehr-Green P, Tull P, Stellfeld M, et al. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003;25(2):101-106 (Pubitemid 36918347)
12. D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics 2006;118(4):1664-1675 (Pubitemid 46393815)
13. Destefano F. Vaccines and autism: evidence does not support a causal association. Clin Pharmacol Ther 2007;82(6):756-759
14. Baker JP. Mercury, vaccines, and autism: one controversy, three histories. Am J Public Health 2008;98:244-253
15. Fombonne E. Thimerosal disappears but autism remains. Arch Gen Psychiatry 2008;65(1):15-16
16. Gallagher C, Goodman M. Hepatitis B triple series vaccine and developmental disability in US children aged 1-9 years. Toxicol Environ Chem 2008;90(5):997-1008
17. Geier DA, Geier MR. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett 2006;27(4):401-413
18. Woo EJ, Ball R, Landa R, et al. Developmental regression and autism reported to the Vaccine Adverse Event Reporting System. Autism 2007;11(4):301-310 (Pubitemid 47244223)
19. Young HA, Geier DA, Geier MR. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci 2008;271(1-2):110-8 This recent review of the available data indicates a strong association between autism cases and exposure to mercury-containing vaccines.
20. Rapin I, Tuchman RF. What is new in autism? Curr Opin Neurol 2008;21(2):143-149
21. Caronna EB, Milunsky JM, Tager-Flusberg H. Autism spectrum disorders: clinical and research frontiers. Arch Dis Child 2008;93(6):518-523 (Pubitemid 352025771)
22. Lintas C, Persico AM. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. J Med Genet 2009;46:1-8 A good review of genetic disorders associated with autism.
23. Palmieri L, Papaleo V, Porcelli V, et al. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry 2008. [Epub ahead of print] An interesting report not only of a mitochondrial dysfunction on autism, but also of a strong association with allergies.
24. Garbett K, Ebert PJ, Mitchell A, et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 2008;30(3):303-311
25. Lintas C, Sacco R, Garbett K, et al. Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Mol Psychiatry 2008;14(7):705-718
26. Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006;29(7):349-358 (Pubitemid 44108247)
27. Cai G, Edelmann L, Goldsmith JE, et al. Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genomics 2008;1:50 A potential rapid screening of a genetic problem associated with a small percentage of autistic cases.
28. Wang K, Zhang H, Ma D, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 2009;459:528-533 Important study showing gene abnormalities associated with encoding neuronal cell adhesion molecules in autism.
29. Glessner JT, Wang K, Cai G, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009;459:569-573 Important study showing gene abnormalities associated with encoding neuronal cell adhesion molecules in autism.
30. Strom SP, Stone JL, Ten B, et al. High-density SNP association study of the 17q21 chromosomal region linked to autism identifies CACNA1G as a novel candidate gene. Mol Psychiatry 2009. [Epub ahead of print] Important study showing gene abnormalities associated with encoding neuronal cell calcium channels in autism.
31. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006;141(8):947-956 (Pubitemid 44905454)
32. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80(6):1611-1617 (Pubitemid 41103861)
33. Carvalho CM, Chew EH, Hashemy SI, et al. Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity. J Biol Chem 2008;283(18):11913-11923
34. James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB 2009. [Epub ahead of print]
35. Geier DA, Kern JK, Garver CR, et al. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 2009;34(2):386-393 Important study showing increased oxidative stress and reduced detoxification ability in patients with ASDs.
36. Geier DA, Kern JK, Garver CR, et al. Biomarkers of environmental toxicity and susceptibility in autism. J Neurol Sci 2008;280(1-2):101-108 Important study showing increased oxidative stress and reduced detoxification ability, especially for mercury, in patients with ASDs.
37. Sajdel-Sulkowska EM, Lipinski B, Windom H, et al. Oxidative stress in autism: elevated cerebellar 3-nitrotyrosine levels. AM J Biochem Biotechnol 2008;4:73-84 Important study showing increased oxidative stress and increased mercury levels in the cerebellum of patients with ASDs. (Pubitemid 351573641)
38. Yorbik O, Sayal A, Akay C, et al. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids 2002;67(5):341-343 (Pubitemid 35397373)
39. James JS, Melnyk S, Jernigan S, et al. Abnormal transmethylation/ transsulfuration metabolism and DNA hypomethylation among parents of children with autism. J Autism Dev Disord 2008;38(10):1966-1975
40. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins. Life Sci 2004;75(21):2539-2549 (Pubitemid 39195260)
41. Yao Y, Walsh WJ, McGinnis WR, Pratico D. Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol 2006;63(8):1161-1164 (Pubitemid 44232325)
42. Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: A cohort analysis. PloS One 2008;3(11):e3815 Important study showing that there is mitochondrial disease and also a high prevalence of GI symptoms in patients with ASDs.
43. Deth R, Muratore C, Benzecry J, et al. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008;29(1):190-201 Useful review summarizing the evidence for reduced capacity to neutralize free oxygen radicals in ASDs.
44. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry 2005;17(6):485-495 Good review of evidence of brain inflammation in ASDs.
45. Ashwood P, van de Water J. Is autism an autoimmune disease? Autoimmun Rev 2004;3(7-8):557-562 Good review of evidence of brain autoantibodies in ASDs.
46. Ashwood P, Wills S, van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006;80(1):1-15 (Pubitemid 44841805)
47. Cohly HH, Panja A. Immunological findings in autism. Int Rev Neurobiol 2005;71:317-341
48. Gregg JP, Lit L, Baron CA, et al. Gene expression changes in children with autism. Genomics 2008;91(1):22-29 (Pubitemid 350298392)
49. Enstrom AM, Lit L, Onore CE, et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 2009;23:124-133
50. Chez MG, Dowling T, Patel PB, et al. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007;36(6):361-365 Important study showing increased CSF levels of TNF in ASD patients. (Pubitemid 46873913)
51. Zimmerman AW, Jyonouchi H, Comi AM, et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 2005;33(3):195-201 (Pubitemid 41558217)
52. Li X, Chauhan A, Sheikh AM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009;207(1-2):111-116
53. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58(5):445-452 (Pubitemid 32411324)
54. Weizman A, Weizman R, Szekely GA, et al. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am J Psychiatry 1982;139(11):1462-1465
55. Ashwood P, Schauer J, Pessah IN, de Water JV. Preliminary evidence of the in vitro effects of BDE-47 on innate immune responses in children with autism spectrum disorders. J Neuroimmunol 2009;208:130-135
56. Grigorenko EL, Han SS, Yrigollen CM, et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 2008;122(2):e438-45 Important study showing increased blood levels of the pro-inflammatory molecule MIF in ASDs.
57. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005;57(1):67-81 (Pubitemid 40053317)
58. Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997;89:4120-4127 (Pubitemid 27220960)
59. Ashwood P, Enstrom A, Krakowiak P, et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008;204:149-153 Important study showing decreased levels of a potential immunomodulator in ASDs.
60. Gebhardt T, Lorentz A, Detmer F, et al. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1. Gut 2005;54(7):928-934 (Pubitemid 40873903)
61. Gomez G, Ramirez CD, Rivera J, et al. TGF-beta1 inhibits mast cell FcåRI expression. J Immunol 2005;174:5987-5993 (Pubitemid 40663785)
62. Dahlgren J, Samuelsson AM, Jansson T, Holmang A. Interleukin-6 in the maternal circulation reaches the rat fetus in mid-gestation. Pediatr Res 2006;60(2):147-51 Interesting paper showing that high maternal IL-6 could reach the fetus. (Pubitemid 44297583)
63. Smith SE, Li J, Garbett K, et al. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007;27(40):10695-702 Interesting study showing that IL-6 can induce ASD-like behavior in mice. (Pubitemid 47535869)
64. Huang M, Pang X, Karalis K, Theoharides TC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. Cardiovasc Res 2003;59(1):241-9 First report to show that acute stress increases serum IL-6, which is entirely dependent on mast cells. (Pubitemid 36776390)
65. de Boer AG, Breimer DD. Cytokines and blood-brain barrier permeability. Prog Brain Res 1998;115:425-451
66. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000;20:131-147 (Pubitemid 30091452)
67. Vojdani A, Campbell AW, Anyanwu E, et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 2002;129(1-2):168-177 (Pubitemid 34874922)
68. Wills S, Cabanlit M, Bennett J, et al. Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders. Brain Behav Immun 2008;23:64-74
69. Singer HS, Morris CM, Williams PN, et al. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol 2006;178(1-2):149-155 Important study showing the presence of antibrain antibodies in children with ASDs but not in their unaffected siblings.
70. Cabanlit M, Wills S, Goines P, et al. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann NY Acad Sci 2007;1107:92-103 (Pubitemid 47528785)
71. Singer HS, Morris CM, Gause CD, et al. Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol 2008;194(1-2):165-172 Important study showing antifetal brain antibodies in mothers of autistic children, suggesting that the fetal BBB was disrupted in utero.
72. Zimmerman AW, Connors SL, Matteson KJ, et al. Maternal antibrain antibodies in autism. Brain Behav Immun 2007;21(3):351-357
73. Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 2008;29(2):226-231 Important study showing antifetal brain antibodies in mothers of autistic children, suggesting that the fetal BBB was disrupted in utero.
74. Persico AM, Sacco R, Curatolo P, et al. Isolation of principal components in autistic disorder symptomatology and their association with biological endophenotypes. Proc Society for Neuroscience, Washington; 2008 Preliminary report that the only significant association of autism is with history of allergies in a large group of Italian children with ASDs.
75. Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H. Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflamm 2008;5:52
76. Lucarelli S, Frediani T, Zingoni AM, et al. Food allergy and infantile autism. Panminerva Med 1995;37(3):137-141
77. Venter C, Pereira B, Voigt K, et al. Prevalence and cumulative incidence of food hypersensitivity in the first 3 years of life. Allergy 2008;63:354-359 (Pubitemid 351224676)
78. Teufel M, Biedermann T, Rapps N, et al. Psychological burden of food allergy. World J Gastroenterol 2007;13(25):3456-3465 Good paper reviewing psychological adverse effects stemming from food allergies.
79. Lack G. Food allergy. N Engl J Med 2008;359(12):1252-1260
80. Ortolani C, Pastorello EA. Food allergies and food intolerances. Best Pract Res Clin Gastroenterol 2006;20(3):467-483 Good review of the differences between food allergies and intolerance that are often confused.
81. Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol 2007;13(22):3027-3030 (Pubitemid 47045457)
82. Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy. Implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 2007;116:207-235
83. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000;12:449-457 (Pubitemid 30728569)
84. Levy SE, Souders MC, Ittenbach RF, et al. Relationship of dietary intake to gastrointestinal symptoms in children with autistic spectrum disorders. Biol Psychiatry 2007;61(4):492-497
85. Valicenti-McDermott MD, McVicar K, Cohen HJ, et al. Gastrointestinal symptoms in children with an autism spectrum disorder and language regression. Pediatr Neurol 2008;39(6):392-398 Report of a significant association of GI symptoms especially in autistic children who regressed.
86. Nikolov RN, Bearss KE, Lettinga J, et al. Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord 2009;39(3):405-413
87. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 2005;51(2):77-85 (Pubitemid 40522799)
88. Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ 2002;325(7361):419-21 Well-researched epidemiological study showing no known GI pathologic entity in ASDs. (Pubitemid 34969792)
89. Wakefield AJ, Ashwood P, Limb K, Anthony A. The significance of ileo-colonic lymphoid nodular hyperplasia in children with autistic spectrum disorder. Eur J Gastroenterol Hepatol 2005;17(8):827-836 (Pubitemid 41073320)
90. Krigsman A, Boris M, Goldblatt A, Scott C. Review of clinical presentation and histologic findings at ileocolonoscopy in children with autistic spectrum disorder and chronic gastrointestinal symtoms. Autism Res 2008. [Epub ahead of print]
91. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr 2005;94(4):386-393 (Pubitemid 40490888)
92. Bode L, Salvestrini C, Park PW, et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 2008;118(1):229-238 Experimental study showing that intestinal integrity involves heparan sulfate.
93. Lencer WI. Patching a leaky intestine. N Engl J Med 2008;359(5):526-528
94. Alberti A, Pirrone P, Elia M, et al. Sulphation deficit in 'low-functioning' autistic children: a pilot study. Biol Psychiatry 1999;46(3):420-424
95. Menage P, Thibault G, Martineau J, et al. An IgE mechanism in autistic hypersensitivity? Biol Psychiatry 1992;31(2):210-212
96. Bakkaloglu B, Anlar B, Anlar FY, et al. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008;12:476-9 Important study showing a positive history of 'allergic' symptoms in patients with ASDs in the absence of serum markers of atopy.
97. Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002;127:147-152
98. Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001;25:577-582 (Pubitemid 32506765)
99. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625 (Pubitemid 32506768)
100. Available from: www.tmsforacure.org
101. Theoharides TC, Doyle R, Francis K, et al. Novel therapeutic targets for autism. Trends Pharmacol Sci 2008;29(8):375-382
102. Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002;128:344-50 First paper to show that mastocytosis patients also have increased serum IL-6 levels.
103. Croen LA, Grether JK, Yoshida CK, et al. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 2005;159(2):151-157
104. Comi AM, Zimmerman AW, Frye VH, et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999;14(6):388-394
105. Theoharides TC, Kalogeromitros D. The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci 2006;1088:78-99 (Pubitemid 47092046)
106. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as 'tunable' effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749-786 Excellent review of the versatile functions of mast cells.
107. Bachelet I, Levi-Schaffer F. Mast cells as effector cells: a co-stimulating question. Trends Immunol 2007;28(8):360-365 (Pubitemid 47082507)
108. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004;146:1-12 A useful review of a number of diseases involving neurogenic inflammation and how acute stress worsens their symptoms through activation of mast cells.
109. Dimitriadou V, Rouleau A, Trung Tuong MD, et al. Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. Neuroscience 1997;77:829-839 (Pubitemid 27092139)
110. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, et al. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res 1999;849:1-15
111. Stead RH, Dixon MF, Bramwell NH, et al. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 1989;97:575-585 First indication of possible functional associations between mast cells and nerves in the gut.
112. Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 2004;25:266-273 (Pubitemid 38501673)
113. Redegeld FA, Nijkamp FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol 2005;24:181-185
114. Kempuraj D, Tagen M, Iliopoulou BP, et al. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008;155:1076-1084 First report that human mast cells can superactivate T cells, a process inhibited by the natural flavonoid luteolin.
115. Carraway R, Cochrane DE, Lansman JB, et al. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. J Physiol 1982;323:403-414 (Pubitemid 12180916)
116. Janiszewski J, Bienenstock J, Blennerhassett MG. Picomolar doses of substance P trigger electrical responses in mast cells without degranulation. Am J Physiol 1994;267:C138-45 (Pubitemid 2128128)
117. Kulka M, Sheen CH, Tancowny BP, et al. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008;123(3):398-410 (Pubitemid 351171192)
118. Frossi B, de Carli M, Daniel KC, et al. Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/ Ref-1-dependent pathway. Eur J Immunol 2003;33:2168-2177 (Pubitemid 37010034)
119. Kempuraj D, Hogan J, Zhang B, et al. Mercury chloride triggers human mast cells to release vascular endothelial growth factor (VEGF)-relevance to autism. 96th Annual Meeting, The Americal Association of Immunologisits, May 8-12. Immunology; 2009
120. Elferink JG. Thimerosal: a versatile sulfhydryl reagent, calcium mobilizer, and cell function-modulating agent. Gen Pharmacol 1999;33(1):1-6 (Pubitemid 29292425)
121. Strenzke N, Grabbe J, Plath KE, et al. Mercuric chloride enhances immunoglobulin E-dependent mediator release from human basophils. Toxicol Appl Pharmacol 2001;174(3):257-263 (Pubitemid 32747836)
122. Salamon P, Shoham NG, Gavrieli R, et al. Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 2005;60(10):1316-1319 (Pubitemid 41297530)
123. Nakae S, Suto H, Iikura M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006;176(4):2238-2248 (Pubitemid 43201671)
124. Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007;217:65-78 Comprehensive review of increasing evidence that mast cells can release different mediators in response to a variety of triggers selectively without degranulation. (Pubitemid 46718152)
125. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. Nature 1982;297:229-231 (Pubitemid 12066450)
126. Okayama Y. Mast cell-derived cytokine expression induced via Fc receptors and Toll-like receptors. Chem Immunol Allergy 2005;87:101-110 (Pubitemid 43093182)
127. Varadaradjalou S, Feger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003;33:899-906 One of early reports that activation of different mast cell TLRs leads to secretion of different mediators. (Pubitemid 36546677)
128. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003;170:1625-1629 One of early reports that activation of different mast cell TLRs lead to secretion of different mediators.
129. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 2004;114(1):174-182 (Pubitemid 39005135)
130. Ikeda RK, Miller M, Nayar J, et al. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J Immunol 2003;171(9):4860-4867 (Pubitemid 37310608)
131. Arvola T, Ruuska T, Keranen J, et al. Rectal bleeding in infancy: clinical, allergological, and microbiological examination. Pediatrics 2006;117(4):e760-8 (Pubitemid 46071481)
132. Dunn SJ, Greenberg HB, Ward RL, et al. Serotypic and genotypic characterization of human serotype 10 rotaviruses from asymptomatic neonates. J Clin Microbiol 1993;31(1):165-169 Evidence that there is exposure to rotavirus in neonates.
133. Difazio MP, Braun L, Freedman S, Hickey P. Rotavirus-induced seizures in childhood. J Child Neurol 2007;22(12):1367-1370
134. Oslejskova H, Dusek L, Makovska Z, et al. Complicated relationship between autism with regression and epilepsy. Neuro Endocrinol Lett 2008;29(4):558-570
135. Pehlivanidis C, Fotoulaki M, Boucher W, et al. Acute stress-induced seizures and loss of consciousness in a ten-year-old boy with cutaneous mastocytosis. J Clin Psychopharmacol 2002;22:221-4 Interesting case report of stress-induced seizures in a child with cutaneous mastocytosis. (Pubitemid 34289400)
136. Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 2003;171(9):4830-6 First evidence that IL-1 can stimulate selective release of IL-6 without degranulation from human mast cells. (Pubitemid 37310604)
137. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005;174:7665-75 First evidence that human mast cells express CRH-R1 receptors, activation of which leads to selective VEGF release. (Pubitemid 40806271)
138. Theoharides TC, Weinkauf C, Conti P. Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol 2004;24:577-581
139. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 2007;12:1615-1628
140. White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 2009;29:216-229
141. Gillott A, Standen PJ. Levels of anxiety and sources of stress in adults with autism. J Intellect Disabil 2007;11(4):359-370 Good paper showing that the level of anxiety is higher in patients with ASDs. (Pubitemid 350120860)
142. Jansen LM, Gispen-de Wied CC, van der Gaag RJ, van EH. Differentiation between autism and multiple complex developmental disorder in response to psychosocial stress. Neuropsychopharmacology 2003;28(3):582-590 First paper showing that patients with ASDs cannot cope with stressors.
143. Tani P, Lindberg N, Matto V, et al. Higher plasma ACTH levels in adults with Asperger syndrome. J Psychosom Res 2005;58(6):533-536 (Pubitemid 41206849)
144. Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm Res 2006;66(4):182-188
145. Geier DA, Geier MR. A prospective assessment of androgen levels in patients with autistic spectrum disorders: biochemical underpinnings and suggested therapies. Neuro Endocrinol Lett 2007;28(5):565-573
146. Theoharides TC, Spanos CP, Pang X, et al. Stress-induced intracranial mast cell degranulation. A corticotropin releasing hormone-mediated effect. Endocrinology 1995;136:5745-5750 First paper showing that acute stress can activate brain mast cells through CRH.
147. Esposito P, Chandler N, Kandere-Grzybowska K, et al. Corticotropin- releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002;303:1061-1066 (Pubitemid 35424390)
148. Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001;888:117-127 (Pubitemid 32056268)
149. Theoharides TC. Mast cells: the immune gate to the brain. Life Sci
150. Silver R, Silverman A-J, Vitkovic L, Lederhendler II. Mast cells in the brain: evidence and functional significance. Trends Neurosci 1996;19:25-31 (Pubitemid 26011580)
151. Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology 1998;139:403-413 First paper showing that CRH can increase vascular permeability by activating mast cells. (Pubitemid 28166335)
152. Crompton R, Clifton VL, Bisits AT, et al. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J Clin Endocrinol Metab 2003;88:5427-5432 Clear evidence that CRH can increase human skin vascular permeability by activating local mast cells through specific receptors. (Pubitemid 37452749)
153. Akin C, Valent P, Escribano L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006;6(4):282-288 (Pubitemid 44056824)
154. Theoharides TC, Kempuraj D, Marchand J, et al. Urticaria pigmentosa associated with acute stress and lesional skin mast cell expression of CRF-R1. Clin Exp Dermatol 2009;34:e163-6 First case report showing that acute stress may worsen urticaria pigmentosa by CRH activation of CRH-R1 receptors on lesional skin mast cells.
155. Theoharides TC, Letourneau R, Patra P, et al. Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Dig Dis Sci 1999;44:87S-93S First evidence that acute stress can disrupt, and chondroitin sulfate protect, the intestinal barrier. (Pubitemid 29450797)
156. Castagliuolo I, Lamont JT, Qiu B, et al. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol 1996;271:884-892 (Pubitemid 26404739)
157. Kokkotou E, Torres D, Moss AC, et al. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol 2006;177(5):3355-61 Well-designed animal study showing that CRH-R is involved in intestinal inflammation. (Pubitemid 44277855)
158. La Fleur SE, Wick EC, Idumalla PS, et al. Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. Proc Natl Acad Sci USA 2005;102(21):7647-52 Good study showing divergent effects of CRH-R2 activation on intestinal function and inflammation.
159. Wallon C, Yang P, Keita AV, et al. Corticotropin releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50-58 Excellent paper showing that CRH activates local intestinal mast cells and increases permeability in human colon biopsies.
160. Umathe SN, Bhutada PS, Jain NS, et al. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice. Neuropeptides 2008;42(4):399-410
161. Umathe SN, Dixit PV, Wanjari MM, Ullewar MP. Leuprolide-a GnRH agonist-prevents restraint stress-induced immunosuppression via sex steroid-independent peripheral mechanism in mice. Int Immunopharmacol 2008;8(1):71-79
162. Barreau F, Cartier C, Leveque M, et al. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay. J Physiol 2007;580(Pt 1):347-356 (Pubitemid 46470663)
163. Barreau F, Salvador-Cartier C, Houdeau E, et al. Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut 2008;57(5):582-590 (Pubitemid 351579968)
164. Wright RJ, Finn P, Contreras JP, et al. Chronic caregiver stress and IgE expression, allergen-induced proliferation, and cytokine profiles in a birth cohort predisposed to atopy. J Allergy Clin Immunol 2004;113(6):1051-1057 (Pubitemid 38857985)
165. Theoharides TC, Doyle R. Autism, gut-blood-brain barrier and mast cells. J Clin Psychopharmacol 2008;28(5):479-83 Editorial stressing the role of mast cells in increasing the permeability of the gut-blood-brain barrier and brain inflammation, as they relate to ASDs.
166. Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 2007;8(11):1579-1603 (Pubitemid 47296548)
167. Broadstock M, Doughty C, Eggleston M. Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism 2007;11(4):335-348 (Pubitemid 47244226)
168. Rogers SJ, Vismara LA. Evidence-based comprehensive treatments for early autism. J Clin Child Adolesc Psychol 2008;37(1):8-38
169. Findling RL. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. J Clin Psychiatry 2005;66(Suppl 10):26-31 (Pubitemid 43133211)
170. Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008;16(2):97-112 (Pubitemid 351549820)
171. West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009;23(2):75-89
172. Liptak GS, Stuart T, Auinger P. Health care utilization and expenditures for children with autism: data from U.S. national samples. J Autism Dev Disord 2006;36(7):871-879 (Pubitemid 44440106)
173. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2007;17(3):348-355 (Pubitemid 47067958)
174. Gerhard T, Chavez B, Olfson M, Crystal S. National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder. J Clin Psychopharmacol 2009
175. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30(3):582-589 (Pubitemid 40271160)
176. Tandon M, Pruett JR Jr. An overview of the use of antidepressants in children and adolescents. Mo Med 2008;105(1):79-84
177. Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J Clin Invest 2008;118(1):6-14 Excellent review of the basis for use of antisychotics in ASDs and lack of any beneficial effect on core symptoms of ASDs.
178. Morgan S, Taylor E. Antipsychotic drugs in children with autism. BMJ 2007;334(7603):1069-1070
179. Chavez B, Chavez-Brown M, Sopko MA, et al. Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs 2007;9(4):249-266 (Pubitemid 47295845)
180. McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008;69(Suppl 4):15-20
181. Mandell DS, Morales KH, Marcus SC, et al. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 2008;121(3):e441-8
182. Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008;18(2):157-178 (Pubitemid 351591438)
183. Research units on pediatric psychparmacology autism network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62(11):1266-1274
184. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347(5):314-321 (Pubitemid 34815353)
185. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs 2007;9(5):343-354 (Pubitemid 47557115)
186. Peachell PT, Pearce FL. Divalent cation dependence of the inhibition by phenothiazines of mediator release from mast cells. Br J Pharmacol 1989;97(2):547-555 Interesting early evidence that certain phenothiazines can inhibit mast cells.
187. Akhondzadeh S, Erfani S, Mohammadi MR, et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J Clin Pharm Ther 2004;29(2):145-150 Interesting study showing that the nonspecific histamine and serotonin receptor antagonist cyproheptadine contributes to reduction of ASD symptoms over that of haloperidol. (Pubitemid 38482479)
188. Hranilovic D, Bujas-Petkovic Z, Vragovic R, et al. Hyperserotonemia in adults with autistic disorder. J Autism Dev Disord 2007;37(10):1934-1940 Intriguing evidence indicating a high level of serum serotonin in ASDs.
189. de Giorgio R, Barbara G, Furness JB, Tonini M. Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol Sci 2007;28(9):473-481 (Pubitemid 47368703)
190. Curtis LT, Patel K. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): a review. J Altern Complement Med 2008;14(1):79-85 Comprehensive review of nonpharmacologic approaches in ASDs. (Pubitemid 351185434)
191. Adams JB. Summary of biomedical treatments for autism. Autism Research Institute (ARI) Publication 2008;40:1-27 Comprehensive review of nonpharmacologic approaches in ASDs.
192. Weber W, Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am 2007;4(6):983-1006 (Pubitemid 350179896)
193. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009;89(1):425-430
194. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000;52:673-751 Comprehensive review, selected as a 'classic' of the beneficial effects of flavonoids in inflammatory diseases.
195. Beretz A, Cazenave JP, Anton R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: structure-activity relationships. Agents Actions 1982;12:382-387 Evidence that select flavonoids inhibit serotonin release from platelets.
196. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 2008;105(21):7534-9 Important study showing that microglia can release IL-6, which can be inhibited by the flavonoid luteolin. (Pubitemid 351830053)
197. Sharma V, Mishra M, Ghosh S, et al. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 2007;73(1-3):55-63 (Pubitemid 46710246)
198. Kumar A, Goyal R. Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice. J Med Food 2008;11(3):469-73 Interesting study showing that acute stress can induce ASD-like symptoms and decrease glutathione levels in mice, while the flavonoid luteolin reverses these effects.
199. Kimata M, Shichijo M, Miura T, et al. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000;30:501-508 (Pubitemid 30253188)
200. Kempuraj D, Madhappan B, Christodoulou S, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005;145:934-944 Comparative study of the ability of select flavonoids to inhibit cytokine secretion from human mast cells. (Pubitemid 41129015)
201. Kandere-Grzybowska K, Kempuraj D, Cao J, et al. Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol 2006;148:208-215 (Pubitemid 43873039)
202. Harwood M, Nielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45(11):2179-2205 A recent comprehensive review concluding that quercetin is safe to use as a dietary supplement. (Pubitemid 47451573)
203. Manach C, Donovan JL. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic Res 2004;38(8):771-785 (Pubitemid 39077365)
204. Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000;56(8):545-553
205. Theoharides TC, Patra P, Boucher W, et al. Chondroitin sulfate inhibits connective tissue mast cells. Br J Pharmacol 2000;131:1039-1049 First indication that the proteoglycan chondroitin sulfate can inhibit mast cells, in addition to its well-known action to protect mucosal surfaces. (Pubitemid 30953553)
206. Vasiadi M, Kalogeromitros K, Kempuraj D, et al. Rupatadine inhibits pro-inflammatory mediator secretion from human mast cells. Clin Exp Allergy 2009. In press First report that an antihistamine and platelet-activation factor (PAF) blocker inhibits mast cell activation.
207. Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother 2006;40(6):1086-1095 (Pubitemid 43886966)
208. Barke KE, Hough LB. Opiates, mast cells and histamine release. Life Sci 1993;53:1391-1399 (Pubitemid 23288945)
209. Bertoglio K, Hendren RL. New developments in autism. Psychiatr Clin North Am 2009;32(1):1-14
210. Theoharides TC, Wang L, Pang X, et al. Cloning and cellular localization of the rat mast cell 78kD protein phosphorylated in response to the mast cell 'stabilizer' cromolyn. J Pharmacol Exp Ther 2000;294:810-821 First report of the cloning of a particular phosphoprotein, the expression of which has an inverse relationship with mast-cell activation.
211. Tagen M, Elorza A, Boucher W, et al. The mitochondrial uncoupling protein 2 (UCP2) inhibits mast cell activation and reduces histamine content. J Immunol 2009. In press First report that low expression of a mitochondrial protein known to regulate the production of reactive oxygen species permits high mast-cell activation.
212. Kamide R, Niimura M, Ueda H, et al. Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine. Ann Allergy 1989;62:322-325 (Pubitemid 19116405)
213. Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One 2008;3(11):e3815
214. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009;66(6):583-590
215. Volkmar FR. Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior. Arch Gen Psychiatry 2009;66(6):581-582